ATE452982T1 - Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo - Google Patents

Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo

Info

Publication number
ATE452982T1
ATE452982T1 AT99401687T AT99401687T ATE452982T1 AT E452982 T1 ATE452982 T1 AT E452982T1 AT 99401687 T AT99401687 T AT 99401687T AT 99401687 T AT99401687 T AT 99401687T AT E452982 T1 ATE452982 T1 AT E452982T1
Authority
AT
Austria
Prior art keywords
cells
vitro
vivo
administration
nucleic acids
Prior art date
Application number
AT99401687T
Other languages
English (en)
Inventor
Francois Lemoine
David Klatzmann
Mojgan Movassagh
Jean-Loup Salzmann
Original Assignee
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Curie filed Critical Univ Paris Curie
Application granted granted Critical
Publication of ATE452982T1 publication Critical patent/ATE452982T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99401687T 1998-07-10 1999-07-06 Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo ATE452982T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11328098A 1998-07-10 1998-07-10

Publications (1)

Publication Number Publication Date
ATE452982T1 true ATE452982T1 (de) 2010-01-15

Family

ID=22348556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99401687T ATE452982T1 (de) 1998-07-10 1999-07-06 Verfahren zur verabreichng von nukleinsäuren in zellen in vitro oder ex vivo

Country Status (4)

Country Link
EP (1) EP0995802B1 (de)
JP (1) JP2000139478A (de)
AT (1) ATE452982T1 (de)
DE (1) DE69941836D1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493789B2 (en) * 2014-04-24 2016-11-15 Miltenyi Biotec Gmbh Automated generation of genetically modified stem cells
CN113736828A (zh) 2014-11-05 2021-12-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
EP4342978A3 (de) * 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Goldoptimierte car-t-zellen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017492A (en) * 1986-02-27 1991-05-21 Life Technologies, Inc. Reverse transcriptase and method for its production
DE69634606D1 (de) * 1995-10-16 2005-05-19 Dana Farber Cancer Inst Inc Neue expressionsvektoren und verfahren zu deren verwendung
AU2998597A (en) * 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
CA2365655A1 (en) * 1999-03-15 2000-09-21 Chiron Corporation Retrovirus producting cells utilizing a high multiplicity of transduction

Also Published As

Publication number Publication date
EP0995802A3 (de) 2001-01-10
EP0995802A2 (de) 2000-04-26
EP0995802B1 (de) 2009-12-23
DE69941836D1 (de) 2010-02-04
JP2000139478A (ja) 2000-05-23

Similar Documents

Publication Publication Date Title
Baramova et al. Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
DE59912118D1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
ATE85361T1 (de) Molekulare zuechtung.
ES8800343A1 (es) Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia
ATE87663T1 (de) Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
ATE195148T1 (de) Prozess zur rekombinanten herstellung von hiv-2 - proteinen sowie zellen, die hiv-2 - proteine exprimiert
DE69720026T2 (de) Verfahren zur herstellung von d-aminosäuren durch direkte gärung
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
DE3851289D1 (de) Verfahren zur Züchtung rekombinanter Zellen.
ATE78055T1 (de) Verfahren zur herstellung von proteinen und transformierten zellen und dna-konstruktionen zur korrektur von mankos und wirtszellen sowie deren herstellung und verwendung.
DE3588008D1 (de) Hefestämme zur erzeugung cellulolytischer enzyme und verfahren und mittel zu deren herstellung.
ATE391175T1 (de) Multidrug resistenz gen
DE69131069D1 (de) Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
DK684087A (da) Fremgangsmaade til fremstilling af enkephalinase og dna-isolater, rekombinante udtrykkelsesvektorer og transformerede celler til anvendelse ved fremgangsmaaden samt fremgangsmaade til proevning af enkephalinase-aktivitet og farmaceutiske praeparater til behandling af sygdomme formidlet af endogene peptider
ATE339511T1 (de) Natürliche oder synthetische retroelement- sequenzen, die die insertion von nukleotiden in eukaryotische zellen erlauben
ES8301503A1 (es) Procedimiento para la produccion de un microorganismo gene- ticamente modificado
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
DE69941836D1 (de) Verfahren zur Verabreichng von Nukleinsäuren in Zellen in vitro oder ex vivo
ES2076926T3 (es) Produccion por tecnologia genetica de factor xiiia.
DE60038630D1 (de) Verfahren zur ex vivo bildung von säugetier-knochen und dessen verwendungen
DE68929296D1 (de) Verfahren zur biochemischen Oxidation von Steroiden sowie dafür verwendbare, genetisch manipulierte Zellen
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.
DE69425809D1 (de) Methoden zur Herstellung von Protein C

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties